CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It.
The expansion is the announcement. Payers covering 165 million pledged to align with a model none of their members can join.
Athithi Verma
Radiopharmaceuticals: sixteen years of deal data on where the field goes next
Buyers have concluded that radiopharmaceuticals are a platform business, and they are paying platform prices.
The UK Commission Wants L-Plates for AI and an End to One-Time Approval
Coverage is calling these new AI rules. What they propose is replacing the single approval decision with supervised entry and permanent monitoring.
Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar.
Most partnership disputes turn on what data meant. Both sides here accept the published numbers were wrong, and every correction favours the drug.
Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug
The clinical case was settled before the regulatory one. Clinicians held an NCCN recommendation with no lawful product to act on it.
Behind the Headlines: How the Leaders Really Performed
Read together rather than one at a time, the quarter divides along four lines, and none of them is visible in a headline growth rate.
Korea adds Pergoveris pen to reimbursement rolls, vial already covered
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
CDA-AMC reverses course, backs Leqembi’s first ruling content still undisclosed
Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
Nine More Drugmakers Signed MFN Deals. The Coalition Formed to Fight Them Did Not.
The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.
Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.
The lane determines the timeline, and it is set long before you file. Model the Korean queue, not the approval date.